Sangamo BioSciences Announces Participation At Upcoming Investor Conferences
RICHMOND, Calif., Nov. 10, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer, will participate in the following conferences in November.
Jefferies 2016 London Healthcare Conference, London, UK, November 16-17, 2016
Dr. Macrae will present an update on the Company's therapeutic development programs on Thursday, November 17th at 2:00 pm GMT. The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentation for two weeks after the event.
28th Annual Piper Jaffray Healthcare Conference, New York, NY, November 29-30, 2016
Dr. Macrae will participate in a panel discussion on Tuesday, November 29th at 3:00 pm ET. Webcasting services are not provided for this session.
Sangamo BioSciences, Inc. is focused on Pioneering Genetic Cures™ for monogenic and infectious diseases by deploying its AAV-based gene therapy platform, and therapeutic genome editing and gene regulation platforms based on its novel zinc finger DNA-binding protein technology. The Company's proprietary zinc finger nuclease (ZFN)-mediated in vivo genome editing approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders MPS I and MPS II. Sangamo has initiated a Phase 1/2 clinical trial for hemophilia B, the first in vivo genome editing application cleared by the FDA. In addition, Sangamo has Phase 1/2 and Phase 2 clinical programs in HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, including sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington's disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sangamo-biosciences-announces-participation-at-upcoming-investor-conferences-300360935.html
SOURCE Sangamo BioSciences, Inc.
Released November 10, 2016